从1988年11月到1994年12月,共有567名女性志愿者在国立台湾大学医院参加了Norplant植入研究。经过29个月的中位随访,529例病例中只有3例怀孕(5年内每100名使用者累计怀孕1.2例).3例流产中2例的染色体分析显示46,XX/46,XX,inv(3)和46,XX。月经问题是最常见的不良反应,也是停药的主要原因(65%,108/166)。延续率为90%,78%,70%,61%,在插入后1、2、3、4和5年结束时,为42%,分别。在21名希望怀孕的患者中,去除Norplant植入物后不久,生育能力复发。数据表明,Norplant植入物系统是一种非常有效的,安全,和长效的可逆避孕方法。将这种避孕系统引入台湾的计划生育计划是值得的。
在1988年11月至1994年12月期间,国立台湾大学医院的健康提供者在Norplant植入研究中招募了567名年龄在17-47岁之间的女性,该研究旨在评估Norplant作为另一种避孕方法选择的益处和副作用。他们追踪妇女的中位数为29个月。38例失访。5年避孕有效率为98.8%。3次妊娠(2次宫内和1次异位)发生在24日,45岁,47个月的使用。没有一个怀孕的妇女体重超过70公斤。流产的胎儿中有两个染色体异常(46,XX/46,XX,inv(3)and46,XX).29.9%的Norplant用户有月经问题。尽管有19.7%的Norplant使用者出现不规则出血,使用Norplant后血红蛋白水平增加(p0.05)。甘油三酯和总胆固醇水平降低(p<0.05)。没有女性发生血栓栓塞。Norplant在1年内的延续率为89.7%,2年的78%,70%在3年内,4年时占61%,5年为42.4%。移除植入物的主要原因是月经问题(108)。在5年之前停止使用Norplant的所有166名妇女和在5年结束时停止使用Norplant的16名妇女中,在没有X射线或超声鉴定的情况下,在一次坐姿中取出了植入物。停止Norplant怀孕的妇女中有78%在去除后的一年内怀孕。所有的婴儿都是正常的。这些发现表明Norplant是一种安全的,有效,和可接受的避孕方法,计划生育计划应将Norplant引入其避孕组合。
From November 1988 to December 1994, a total of 567 female volunteers were enrolled in Norplant implant studies at the National Taiwan University Hospital. After a median follow-up of 29 months, only 3 of the 529 available cases became pregnant (a cumulative rate of 1.2 pregnancies per 100 users over 5 years). Chromosome analysis of 2 of the 3 abortuses revealed 46,XX/46,XX,inv(3) and 46,XX. Menstrual problems were the most common adverse effects and were also the main reason for discontinuation (65%, 108/166). The continuation rate was 90%, 78%, 70%, 61%, and 42% at the end of 1, 2, 3, 4, and 5 years after insertion, respectively. In the 21 patients who wished to become pregnant, fertility recurred soon after removal of the Norplant implants. The data suggested that the Norplant implants system is a highly effective, safe, and long-acting method of reversible contraception. It would be worthwhile to introduce this contraceptive system to Taiwan\'s family planning program.
Between November 1988 and December 1994 health providers at the National Taiwan University Hospital enrolled 567 women aged 17-47 in the Norplant implant studies that aimed to evaluate the benefits and side effects of Norplant as another contraceptive method choice. They followed the women for a median of 29 months. 38 cases were lost to follow-up. The 5-year contraceptive effectiveness rate was 98.8%. The 3 pregnancies (2 intrauterine and 1 ectopic) occurred during the 24th, 45th, and 47th months of use. None of the women who became pregnant weighed more than 70 kg. Two of the aborted fetuses had chromosomal abnormalities (46,XX/46,XX,inv(3) and 46,XX). 29.9% of the Norplant users had menstrual problems. Even though irregular bleeding occurred to 19.7% of Norplant users, hemoglobin levels increased after Norplant use (p 0.05). Triglycerides and total cholesterol levels decreased (p 0.05). None of the women developed thromboembolism. The Norplant continuation rate was 89.7% at 1 year, 78% at 2 years, 70% at 3 years, 61% at 4 years, and 42.4% at 5 years. The leading reason for implant removal was menstrual problems (108). The implants were removed during one sitting without x-ray or ultrasound identification in all 166 women who stopped using Norplant before 5 years and the 16 women who stopped using it at the end of 5 years. 78% of women who discontinued Norplant to become pregnant were pregnant within one year following removal. All their infants were normal. These findings suggest that Norplant is a safe, effective, and acceptable contraceptive method and that the family planning program should introduce Norplant to its contraceptive mix.